Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients

References

• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• DCCT Study Group. The Effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004;291:335-42
   PubMed Web of Science ®Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J Am Med Assoc 2002;287:360-72
   PubMed Web of Science ®Google Scholar
• Mentlein R. Dipeptidyl peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24
   PubMed Web of Science ®Google Scholar
• Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47:1663-70
   PubMed Web of Science ®Google Scholar
• Madsbad S, Krarup T, Deacon CF, et al. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008;11:491-9
   PubMed Web of Science ®Google Scholar
• Nauck MA, Vilsboll T, Gallwitz B, et al. Incretin-based therapies. Diabetes Care 2009;32:S223-31
   PubMed Web of Science ®Google Scholar
• Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009; 5:262-9
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-13
   PubMed Web of Science ®Google Scholar
• Garcia-Soria G, Gonzalez-Galvez G, Argoud GM, et al. The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus. Diabetes Obes Metab 10;2008:293-300
   Google Scholar
• O'Farrell AM, van Vliet A, Abou Farha K, et al. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. Clin Ther 2007;29:1692-704
   PubMed Web of Science ®Google Scholar
• Phenomix, data on file (No. PHX1149-PROT108)
   Google Scholar
• Phenomix, data on file (Nos. PHX1149-PROT107, PHX1149PK022405R, PHX1149PK082304D, PHX1149PK022505MK)
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Setter SM, Iltz JL, Thams J, et al. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25:2991-3026
   PubMed Web of Science ®Google Scholar
• Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-69
   Google Scholar
• Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. Diabetes Obes Metab 2009;11:978-86
   Google Scholar
• Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009;32:1649-55
   PubMed Web of Science ®Google Scholar
• Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009;11:611-22
   Google Scholar
• Nauck MA, Ellis GC, Fleck PR, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46-55
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. New Engl J Med 1996;334:574-9
   PubMed Web of Science ®Google Scholar
• Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721-49
   Google Scholar
• Phenomix, data on file (No. PHX1149-PROT106)
   Google Scholar
• Pattzi HM, Pitale S, Alpizar M, et al. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab 2010;12:348-55
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Yi B, Kipnes M. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006; 22:1939-47
   PubMed Web of Science ®Google Scholar
• Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 2005;22:255-9
   PubMed Web of Science ®Google Scholar